Speakers - Sachs Associates

CONTACTS
Mr Paul Higham
Chief Executive Officer
Mr Rainer Kramer
Director & Head of Business
Development
ADDRESS
immatics biotechnologies GmbH
Paul-Ehrlich-Straße 15
72076 Tuebingen
Germany
TELEPHONE
+49 7071 5397-0
FAX
+49 7071 5397-900
EMAIL
partnering@immatics.com
info@immatics.com
YEAR FOUNDED
2000
immatics biotechnologies GmbH
www.immatics.com
FINANCIAL SUMMARY
2004/2005: € 14 mn Series A
2007: € 40 mn Series B
2010: € 54 mn Series C
non equity funding total: € 4 mn
COMPANY PROFILE
immatics is a biopharmaceutical company dedicated to the development of innovative cancer
immunotherapeutics.
immatics ’ proprietary technology for the identification of tumor-associated pep¬tides (TUMAPs) enables the
development of novel anti-cancer vaccines for multiple cancer indications. immatics is currently developing
IMA901 for the treatment of renal cell carcinoma in Phase III and IMA910 (in Phase II) for the treatment of
colorectal carcinoma (CRC).
For third product, IMA950, for the treatment of malignant glioma (brain cancer) immatics has entered into two
clinical studies. Further product candidates are currently in pre-clinical development. The furthest advanced of
which are for gastric and lung cancer.
immatics was founded in 2000 as a spin-off from the Institute of Immu¬nology at the University of Tuebingen
(Prof. Hans-Georg Rammensee) and is based in Tuebingen and in Munich, both in Germany.
MANAGEMENT
Paul Higham, CEO
Rainer Kramer, CBO
Harpreet Singh, CSO
Carsten Reinhardt, CMO
t back :: next u
WELCOME PHARMA LICENSING GROUPS
SPEAKERS
PRESENTING COMPANIES SUPPORTING ORGANISATIONS
ORGANISERS